Eli Lilly outpaces Novo in the GLP-1 market with Tirzepatide and emerging blockbusters, signaling future growth. Read more on ...

Eli Lilly's weight loss drugs, especially Zepbound and Mounjaro, have driven impressive revenue growth. Click here to read an ...

Rhythm Pharmaceuticals develops medicines for rare disorders that cause weight gain. The company's only approved product is ...

LLY, NFLX, and GE lead today's top stock picks, with strong growth drivers but face headwinds from pricing, rivals, and costs ...

Business Insider spoke to Eli Lilly's new president of cardiometabolic health, who shared the company's aggressive incretin drug strategy.

Eli Lilly has outpaced Ozempic-maker Novo Nordisk in the race to develop new incretin drugs.The company is set to capture 50% of the $95 billion obesity market by 2050.We got a glimpse into Eli ...

Pfizer and Novo Nordisk have underperformed the market over the past year. Pharmaceutical giants Pfizer (NYSE: PFE) and Novo ...

Cipla is set to enter India's weight management market, addressing the increasing demand for obesity solutions, while also ...

Cipla is preparing to enter the weight-loss drug making sector, heating the competition with US-based Eli Lilly & Co and ...

LLY, NFLX, and GE lead this week???s top research picks as strong demand, growth strategies, and sector tailwinds fuel ...

DelveInsight's Interleukin-17 Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast report includes ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...